Treatment of osteoporosis with Teriparatide rhPTH(1-34).
San Martin
J
J
Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. jsanmartin@lilly.com
D000818:Animals; D015415:Biomarkers; D015519:Bone Density / Q000187:drug effects / Q000502:physiology; D001861:Bone Regeneration / Q000187:drug effects* / Q000502:physiology; D001842:Bone and Bones / Q000187:drug effects* / Q000502:physiology; D004334:Drug Administration Schedule; D050723:Fractures, Bone / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control; D006801:Humans; D010012:Osteogenesis / Q000187:drug effects* / Q000502:physiology; D010024:Osteoporosis / Q000188:drug therapy*; D051381:Rats; D019379:Teriparatide / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
D015415:Biomarkers; D019379:Teriparatide